Results 61 to 70 of about 43,354 (271)

The Relevance of HTLV-1-associated Myelopathy/Tropical Spastic Paraparesis in Iran: A Review Study [PDF]

Reviews in Clinical Medicine, 2019
Human T-cell lymphotropic virus type I (HTLV-I) is a retrovirus, which is the causative agent of adult T-cell leukaemia (ATL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
Masoud Keikha, mohsen Karbalaei Zadeh Babaki, Luiz Augusto Marcondes Fonseca, Jorge Casseb   +3 more
doaj   +1 more source

Harnessing the Therapeutic Potential of Cell Secretomes and Extracellular Vesicles for Craniofacial Regenerative Applications

Journal of Periodontal Research, EarlyView.
The scoping review summarizes the current preclinical and clinical evidence for the use of “cell‐free” therapies in craniofacial (periodontal, bone and soft‐tissue) regeneration. It also aims to highlight key challenges and strategies towards the clinical translation of these therapies.
Siddharth Shanbhag, Magdalena Mayol, Danijel Domic, Madhusudhan Reddy Bobbili, Johannes Grillari, Mariano Sanz, Reinhard Gruber   +6 more
wiley   +1 more source

Increased mortality associated with HTLV-II infection in blood donors: a prospective cohort study

Retrovirology, 2004
Background HTLV-I is associated with adult T-cell leukemia, and both HTLV-I and -II are associated with HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
Smith James W, Garratty George, Nass Catharie C, Wright David J, Wang Baoguang, Orland Jennie R, Newman Bruce, Smith Donna M, Murphy Edward L   +8 more
doaj   +1 more source

Sexual transmission of human T-cell lymphotropic virus type 1 [PDF]

, 2014
Human T-cell lymphotropic virus type 1 (HTLV-1) is endemic in many parts of the world and is primarily transmitted through sexual intercourse or from mother to child.
Casseb, Jorge Simão do Rosário, Paiva, Arthur Maia   +1 more
core   +1 more source

Perceptions of donor screening—Do I always need to tell the truth?

Transfusion Medicine, EarlyView.
Abstract Background The Donor Health Assessment Questionnaire (DHQ) is fundamental to blood safety. We describe attitudes towards truthfulness among first‐time donors who tested positive for transfusion transmissible infections and those who did not.
Sheila F. O'Brien, Lori Osmond, Mindy Goldman   +2 more
wiley   +1 more source

Two Cases of Human T-Lymphotropic Virus Type I-Associated Myelopathy/Tropical Spastic Paraparesis Caused by Living-Donor Renal Transplantation

Case Reports in Neurological Medicine, 2016
In rare instances, recipients of organ transplants from human T-lymphotropic virus type I- (HTLV-I-) positive donors reportedly developed neurologic symptoms due to HTLV-I-associated myelopathy (HAM).
Yasutaka Tajima, Mariko Matsumura, Hiroaki Yaguchi, Yasunori Mito   +3 more
doaj   +1 more source

STAT1: A Novel Target of miR-150 and miR-223 Is Involved in the Proliferation of HTLV-I–Transformed and ATL Cells [PDF]

, 2010
We have previously reported on the deregulation of cellular microRNAs involved in hematopoiesis and inflammation in human T-cell lymphotropic virus type 1 (HTLV-I)–transformed cells.
Moles, Ramona, Bellon, Marcia, Nicot, Christophe   +2 more
core   +2 more sources

Pathogen‐reduced platelet concentrates in France: Impact on the risk of transfusion‐transmitted infections, 2017–2024

Vox Sanguinis, EarlyView.
Abstract Background and Objectives Pathogen reduction (PR) using amotosalen‐UVA was implemented for 100% of platelet concentrates (PCs) in France in November 2017. No bacterial testing was in place earlier. The impact of PR on the risk of transfusion‐transmitted infections (TTIs) from November 2017 to December 2022 (vs.
Syria Laperche, Virginie de la Taille, Pierre Gallian, Elodie Pouchol, Catherine Humbrecht, Alexandre Montembault, Lucile Malard, Caroline Bacquet, Marianne Asso‐Bonnet, Sophie Le Cam, Thierry Peyrard, Pierre Tiberghien   +11 more
wiley   +1 more source

Expression of interleukin 2 receptors on activated human B cells. [PDF]

, 1984
Using anti-Tac, a monoclonal anti-interleukin 2 (IL-2) receptor antibody, we have explored the possibility that certain activated B cells display receptors for IL-2.
Bongiovanni, KF, Depper, JM, Goldman, CK, Greene, WC, Korsmeyer, SJ, Leonard, WJ, Robb, RJ, Sharrow, SO, Waldmann, TA   +8 more
core  

Re‐entry of donors deferred for false‐reactive screening tests in Canada: 10 years post implementation

Vox Sanguinis, EarlyView.
Abstract Background and Objectives Canadian Blood Services implemented a re‐entry programme in 2014. Donors deferred because of false‐reactive or indeterminate screening tests can provide a specimen for re‐entry testing 6 months after their initial test, and resume donating if they test negative for all infectious markers.
Chinchin Wang, Steven J. Drews, Mark Bigham, Mindy Goldman, Sheila F. O'Brien   +4 more
wiley   +1 more source